GlassScriptPhysician profile
Jolene Schlegel
NPI 1063798379
$940.66
in general payments reported to CMS, 2019-2025
24 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.73 · 2022: $133 · 2023: $157 · 2024: $199 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.73 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $125.93 | 2021-2025 | Dupixent |
| Phadia US INC. | $101.79 | 2023-2025 | Immunocap |
| Csl Behring | $76.27 | 2022-2025 | Haegarda, Andembry |
| Takeda Pharmaceuticals U.S.A., INC. | $74.97 | 2022-2024 | Takhzyro, Eohilia, Hyqvia |
| Ionis Pharmaceuticals, INC. | $67.91 | 2025 | Dawnzera |
| Amgen INC. | $62.80 | 2022-2025 | Tezspire |
| Astrazeneca Pharmaceuticals LP | $48.86 | 2022-2024 | Airsupra |
| Grifols USA, LLC | $46.83 | 2023-2025 | Prolastin-C Liquid, Xembify |
| Glaxosmithkline, LLC. | $43.82 | 2021-2025 | Nucala |
| Verona Pharma, INC. | $32.77 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $31.26 | 2022 | |
| Optinose US, INC. | $25.35 | 2022-2023 | |
| Ars Pharmaceuticals Operations, INC. | $23.55 | 2025 | Neffy |
| Genentech USA, INC. | $19.88 | 2024 | Xolair |
| Viatris Specialty LLC | $18.92 | 2025 | Yupelri |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $16.94 | 2025 | Sajazir |
| Pharming Healthcare, INC. | $16.91 | 2025 | Ruconest |
| Baxter Healthcare | $16.59 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $16.56 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.25 | 2025 | |
| Philips North America LLC | $15.81 | 2021 | |
| Mylan Specialty L.P. | $14.72 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.27 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jolene Schlegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.